Aim: To evaluate the bone mineral density at lumbar spine and at femoral neck in a group of young adults in whom Graves’ disease developed during childhood and adolescence. Patients and Methods: We examined 28 patients (5 male, 23 female, age 20.9 ± 3.3 years) who were 11.8 ± 2.9 years old at the onset of Graves’ disease. They were treated either with methimazole (14 patients) or with methimazole plus l-thyroxine (14 patients). At the time of the investigation, 13 patients were considered cured following antithyroid treatment, 2 were still on antithyroid drugs, 3 were on replacement therapy with l-thyroxine because of hypothyroidism, and 10, treated either surgically or with 131I, were on replacement therapy. The bone mineral density was measured at the lumbar spine (L2–L4) and at the femoral neck, using dual-energy X-ray absorptiometry. Results: The spinal bone mineral density SD score was –0.28 ± 1.02, the femoral neck bone mineral density SD score was 0.36 ± 1.02, and both were not different from zero (NS). We did not find any correlation between the bone mineral density of the femoral neck and that of the lumbar spine and the clinical parameters. Conclusion: Graves’ disease, beginning in childhood and adolescence, when appropriately treated, does not affect attainment of peak bone mass.

Keywords:
Graves’ disease, Bone mineral density, Dual-energy X-ray absorptiometry, Antithyroid treatment
1.
Mosekilde L, Eriksen EF, Charles P: Effect of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990;19:35–63.
2.
Wakasugi M, Wakao R, Tawata M, Gan N, Inoue M, Koizumi K, Onaya T: Changes in bone mineral density in patients with hyperthyroidism after attainment of euthyroidism by dual-energy X-ray absorptiometry. Thyroid 1994;4:179–182.
3.
Toh SH, Claunch BC, Brown PH: Effect of hyperthyroidism and its treatment on bone mineral content. Arch Intern Med 1985;145:883–886.
4.
Saggese G, Bertelloni S, Baroncelli GI: Bone mineralization and calciotropic hormones in children with hyperthyroidism: Effects of methimazole therapy. J Endocrinol Invest 1990;13:587–592.
5.
Mora S, Weber G, Marenzi K, Signorini E, Rovelli R, Proverbio MC, Chiumello G: Longitudinal changes of bone density and bone resorption in hyperthyroid girls during treatment. J Bone Miner Res 1999;14:1971–1977.
6.
Lucidarme N, Ruiz JC, Czernichow P, Léger J: Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves’ disease. J Pediatr 2000;137:56–62.
7.
Langdahl Bl, Loft AG, Eriksen EF, Mosekilde L, Charles P: Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated with combined medical therapy. Thyroid 1996;6:161–168.
8.
Melsen F, Mosekilde L: Morphometric and dynamic studies of bone changes in hyperthyroidism. Acta Pathol Microbiol Scand [A] 1977;85:141–150.
9.
Adami S, Kanis JA: Assessment of involutional bone loss: Methodological and conceptual problems. J Bone Miner Res 1995;10:511–517.
10.
Bonjour JP, Theintz G, Law F, Slosman D, Rizzoli R: Peak bone mass. Osteoporos Int 1994;4(suppl 1):7–13.
11.
Matkovic V, Jelic T, Wardlaw GM, Ilich JZ, Goel PK, Wright JK, Andon MB, Smith KT, Heaney RP: Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis: Inference from a cross-sectional model J Clin Invest 1994;93:799–808.
12.
National Osteoporosis Foundation: Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998;8(suppl 4):1–88.
13.
Holmes SJ, Shalet SM: Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Horm Res 1996;45:86–93.
14.
Oikawa M, Kushida K, Takahashi M, Ohishi T, Hoshino H, Suzuki M, Ogihara H, Ishigaki J, Inoue T: Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin Endocrinol (Oxf) 1999;50:171–176.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.